Urticaria unresponsive to antihistaminic treatment: An open study of therapeutic options based on histopathologic features

Página do item simplificado
dc.contributor.authorCriado, Roberta F. J.
dc.contributor.authorCriado, Paulo Ricardo
dc.contributor.authorMartins, Jose Eduardo C.
dc.contributor.authorValente, Neusa Y. S.
dc.contributor.authorMichalany, Nilceo Schwery [UNIFESP]
dc.contributor.authorVasconcellos, Cidia
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:49:25Z
dc.date.available2016-01-24T13:49:25Z
dc.date.issued2008-01-01
dc.description.abstractBackground: the non- or low-sedating H1 receptor antagonists represent the basic therapy for urticaria. Objective: To test an alternative approach to patients unresponsive to conventional treatment. Materials and methods: A total of 22 patients with chronic urticaria unresponsive to conventional antihistamine treatment were enrolled for this study. They had uncontrolled urticaria even using multiple combinations of antihistamines on maximum doses and corticosteroids in short cycles (prednisone 20-40 mg, per os once a day, 3-7 days per month). Cutaneous biopsies of the urticaria lesions were taken. These findings were classified as: (I) a mixture of perivascular dermal inflammatory infiltrate composed of lymphocytes, monocytes and neutrophils and/or eosinophils; (II) inflammatory infiltrate composed chiefly of neutrophils; and (III) inflammatory infiltrate composed mainly of eosinophils. According to histology, the patients were submitted to one of the following therapeutic schemes: class A - antihistamine treatment plus dapsone; class B - colchicine or dapsone; class C montelukast. Results: Four patients in class A, 08 in class B and seven in class C displayed complete control of urticaria after 12 weeks of treatment; one patient in class B and two in class C did not respond to treatment. Two years after discontinuation, 16 patients are still free of urticaria. Conclusions: This study suggests an alternative approach for treating unresponsive chronic urticaria.en
dc.description.affiliationUniv São Paulo, Fac Med, Dept Dermatol, Hosp Clin,LIM 53, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Dermatol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Dermatol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent92-96
dc.identifierhttp://dx.doi.org/10.1080/09546630701499309
dc.identifier.citationJournal of Dermatological Treatment. Abingdon: Taylor & Francis Ltd, v. 19, n. 2, p. 92-96, 2008.
dc.identifier.doi10.1080/09546630701499309
dc.identifier.issn0954-6634
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/30319
dc.identifier.wosWOS:000255366500004
dc.language.isoeng
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal of Dermatological Treatment
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://journalauthors.tandf.co.uk/permissions/reusingOwnWork.asp
dc.subjectantihistaminesen
dc.subjectcolchicinesen
dc.subjectdapsoneen
dc.subjectmontelukasten
dc.subjecturticariaen
dc.titleUrticaria unresponsive to antihistaminic treatment: An open study of therapeutic options based on histopathologic featuresen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral